Industry Pipeline - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Industry Pipeline
Interphex Showcase 2010.

Pharmaceutical Technology
Volume 34, Issue 4, pp. 128-135



Contract manufacturing
A brochure from Ben Venue Laboratories describes the company's contract manufacturing services. Capabilities include the development and production of dosage forms such as sterile suspension, emulsion, liposome, microsphere, lyophilized, and liquid injectables in aqueous or nonaqueous solvent systems. The company produces batch sizes from clinical to commercial scale. Ben Venue Laboratories, Bedford, OH http://www.benvenue.com/ tel. 440.232.3320



Lyophilization services
Hospira's One 2 One business is a leading contract manufacturing organization specializing in injectable fill–finish services. The company meets clients' global manufacturing and supply demands with lyophilization capabilities at its three facilities located in Kansas, Milan, and Melbourne. Hospira One 2 One, Lake Forest, IL http://www.one2onecmo.com/ tel. 224.212.2267



Analytical pharmaceutical services
AAIPharma takes a customer-focused approach to solving drug-development and manufacturing challenges. The company's analytical pharmaceutical services include clinical packaging and distribution, sterile and solid-dose manufacturing, analytical services, validation, regulatory-affairs consulting, formulation development, and oral drug-delivery technologies. AAIPharma, Wilmington, NC http://www.aaipharma.com/ tel. 910.254.7000



Development and manufacturing services
Halo Pharma provides pharmaceutical development and commercial manufacturing services to help customers bring their products to market successfully and quickly. With integrated capabilities in various dosage forms, including tablets, capsules, powders, liquids, ointments, and suppositories, Halo can partner with clients from development through the commercial life of a product. Halo Pharma, Whippany, NJ http://www.halopharma.com/ tel. 973.428.4000



Dosage-form manufacturing
DSM is a global provider of finished dosage-form manufacturing and related services to the pharmaceutical and biopharmaceutical markets. The company performs aseptic filling of liquid and freeze-dried cytotoxic and noncytotoxic compounds; manufactures tablets and capsules; offers pharmaceutical development services; and performs clinical-trial-material manufacturing for solid and injectable dosage forms. DSM, Parsippany, NJ http://www.dsmpharmaceuticals.com/ tel. 973.257.8011


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
21%
To all process for new products only
13%
To select process for new products only
26%
To select processes for both new and legacy products
21%
Do not use QbD
21%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
PhRMA Dismayed by Special 301 Report
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here